HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

MIRAMAR, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and diseases, announced today the data presented for their tetra-valent, second-generation T-Cell Engager (“TCE”) Program based on their novel TRBC platform technology, at the SITC 40^th Annual Meeting, taking place from November 5 to 9, 2025 in National Harbor, Maryland.   

Read more at globenewswire.com